Lewis X component in human milk binds DC-SIGN and inhibits HIV-1 transfer to CD4(+) T lymphocytes

Naarding, M.; Ludwig, I.S.; Groot, F.; Berkhout, B.; Geijtenbeek, T.B.H.; Pollakis, G.; Paxton, W.A.

Published in:
The journal of clinical investigation

DOI:
10.1172/JCI25105

Citation for published version (APA):
Lewis X component in human milk binds DC-SIGN and inhibits HIV-1 transfer to CD4+ T lymphocytes

Marloes A. Naarding,1 Irene S. Ludwig,2 Fedde Groot,1,3 Ben Berkhout,1 Teunis B.H. Geijtenbeek,2 Georgios Pollakis,1 and William A. Paxton1

1Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
2Department of Molecular Cell Biology and Immunology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands.
3Department of Cell Biology and Histology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

DC-specific ICAM3-grabbing non-integrin (DC-SIGN), which is expressed on DCs, can interact with a variety of pathogens such as HIV-1, hepatitis C, Ebola, cytomegalovirus, Dengue virus, Mycobacterium, Leishmania, and Candida albicans. We demonstrate that human milk can inhibit the DC-SIGN–mediated transfer of HIV-1 to CD4+ T lymphocytes as well as viral transfer by both immature and mature DCs. The inhibitory factor directly interacts with DC-SIGN and prevented the HIV-1 gp120 envelope protein from binding to the receptor. The human milk proteins lactoferrin, α-lactalbumin, lysozyme, β-casein, and secretory leukocyte protease inhibitor did not bind DC-SIGN or demonstrate inhibition of viral transfer. The inhibitory effect could be fully alleviated with an Ab recognizing the Lewis X (LeX) sugar epitope, commonly found in human milk. LeX in polymeric form or conjugated to protein could mimic the inhibitory activity, whereas free LeX sugar epitopes could not. We reveal that a LeX motif present in human milk can bind to DC-SIGN and thereby prevent the capture and subsequent transfer of HIV-1 to CD4+ T lymphocytes. The presence of such a DC-SIGN–binding molecule in human milk may both influence antigenic presentation and interfere with pathogen transfer in breastfed infants.

Introduction

DCs can capture an array of infectious agents and present their antigens to T lymphocytes. DCs express, among other receptors, the DC-specific ICAM3-grabbing non-integrin (DC-SIGN) receptor, a C-type lectin, which contains an external calcium-dependent mannos-binding lectin domain (1, 2). DC-SIGN interacts with the envelope glycoprotein gp120 of HIV-1, HIV-2, and SIV (3–8), as well as other pathogens such as hepatitis C (9, 10), Ebola (11), cytomegalovirus (12), Dengue virus (13), Mycobacterium (14–16), Leishmania (17, 18), Candida albicans (19), and Helicobacter pylori (20, 21). DC-SIGN has been implicated as playing an important role in HIV-1 transmission and the establishment of infection (4, 6, 22–25). The interaction of HIV-1 with DC-SIGN can lead to infection of the DCs, or alternatively the virus can be internalized into a trypsin-resistant compartment prior to undergoing transfer to its main target cells, and this mechanism has been shown to greatly enhance infection of T cells in vitro (26, 27).

Mother-to-child transmission (MTCT) of HIV-1 accounts for the majority of HIV-1 infections among children (28). Transmission can occur either in utero, intrapartum, or through breastfeeding (29). It has been recognized that HIV-1 transmission via breastfeeding accounts for 40% of all MTCTs of HIV-1 (30, 31). Relatively little is known with regard to HIV-1 present within human milk and how the virus is transmitted from mother to child. Children exposed to HIV-1 through breastfeeding will encounter both free viral particles as well as cell-associated virus (32, 33). Macrophages in human milk are found at varying concentrations during lactation (34) and are preferentially infected with viruses that utilize the CCR5 coreceptor for viral entry (R5) and that are typically associated with HIV-1 transmission (35, 36). Mammary epithelial cells are present in human milk, and these cells are predominantly infected with viruses utilizing the CXCR4 coreceptor (X4), virus strains that seldom undergo transmission (37, 38). CD4+ T lymphocytes are also present in human milk, and these cells can be infected with both R5 and X4 strains, depending on the cellular phenotype and cell activation status (39, 40). MTCT of HIV-1 via breastfeeding is likely to require the transfer of virus across a mucosal barrier or via breaches in the mucosal surface. The interaction of the HIV-1 gp120 protein with DCs, shown to be present at high concentrations in the tonsils, the upper rim of the esophagus (41, 42), and the intestinal tract (43), may therefore heighten virus capture and transmission. Although DC-SIGN expression has not been analyzed on DCs from all the above-mentioned anatomical sites, high levels of expression have been reported in tonsil material (6).

Several of the proteins present in human milk have been shown to possess antimicrobial activity. Lactoferrin (44–46), lysozyme (47), and secretory leukocyte protease inhibitor (SLPI) (48, 49) have all been shown to exhibit anti–HIV-1 properties in vitro. On the contrary, β-casein has been shown to enhance HIV-1 infection of CD4+ T lymphocytes (44). Oligosaccharides present in human milk include lacto-N-fucopentaose; lacto-N-fucopentaose (LNF) I, II and III; and monofucosyllacto-N-hexaose III; among others (50–52). A number of sugar epitopes to be found in human milk...
are composed of the Lewis group of antigens, including Lewis X (Le\(^X\)) and Lewis Y (Le\(^Y\)) (53), which can be part of a larger oligosaccharide, regardless of whether the sugar is protein associated or not. The Le\(^X\) epitope (Galβ1-4[Fucα1-3]GlcNAc-R) is also included within the LNFP III sugar moiety. This same sugar epitope has been identified in bodily fluids, including saliva, blood, and human milk and has also been shown to be present in a number of pathogens (21) and pathogen extracts (54). Some of the human milk oligosaccharides have been shown to protect against toxins and pathogens involved in childhood diseases (55).

**Results**

The effect of human milk on direct HIV-1 infection of CD4\(^+\) T lymphocytes and DC-SIGN–mediated HIV-1 transfer. We investigated the effect of human milk on direct infection of CD4\(^+\) T lymphocytes by incubating HIV-1 in the presence of several dilutions of human milk from an HIV-1–negative donor taken 6 months into lactation. The 2-fold dilution of human milk demonstrated a significant degree of viral inhibition (>90%; \(P < 0.05\)) in comparison with the PBS control (Figure 1A), which corresponds with previous reports (44–49). We also identify an enhancement to infection at the 1:10 dilution of human milk or PBS for 2 hours, after which several dilutions were made and added to CD4\(^+\) T lymphocytes. For both experiments the CA-p24 concentration was determined on day 7. *\(P < 0.05\) compared with the PBS control.

DC-SIGN–expressing cells can enhance infection of CD4\(^+\) T lymphocytes (4, 8). To study the effect of human milk on DC-SIGN–mediated transfer of HIV-1, we utilized the Raji cell line expressing the DC-SIGN receptor (Raji-DC-SIGN) (8). The same human milk sample as used in the direct infection assay or PBS spiked with HIV-1 primary isolates was incubated with the Raji-DC-SIGN cells for 30 minutes or 2 hours, after which the cells were washed and incubated with activated CD4\(^+\) T lymphocytes and the culture monitored for viral replication. Raji-DC-SIGN cells pre-incubated with PBS spiked with HIV-1 showed efficient transfer to CD4\(^+\) T lymphocytes (Figure 2A, black line). The Raji cell line not expressing DC-SIGN showed no viral transfer, demonstrating that the effect we observed is DC-SIGN dependent (data not shown). Surprisingly, preincubation of Raji-DC-SIGN cells with HIV-1–spiked human milk significantly reduced or blocked transfer of HIV-1 depending on the incubation time (Figure 2A, gray line). Through testing cell viabilities, we demonstrated that the observed inhibition was not due to induced cell death of Raji-DC-SIGN–expressing cells can enhance infection of CD4\(^+\) T lymphocytes (4, 8).

Figure 2

DC-SIGN–dependent transfer of HIV-1 to CD4\(^+\) T lymphocytes is inhibited in the presence of human milk. (A) A 1:2 dilution of human milk of an uninfected mother or PBS was spiked with primary isolates NSI-18 (R5) or SI-19 (X4) before addition to Raji-DC-SIGN cells. After an incubation of 30 minutes or 2 hours, the cells were washed, and activated CD4\(^+\) T lymphocytes were added. Viral replication was measured on days 7, 9, 12, and 14 after infection by determining CA-p24 values using a standard ELISA. The bars represent maximum and minimum CA-p24 values. (B) PBS or serial dilutions of human milk were spiked with JR-CSF (R5) or LAI (X4) before addition of Raji-DC-SIGN cells; after an incubation of 2 hours, the cells were washed with PBS, and stimulated CD4\(^+\) T lymphocytes were added. At day 7, CA-p24 concentrations were determined by standard ELISA. Percent inhibition was determined in reference to the CA-p24 concentration of the corresponding spiked PBS control.
SIGN cells irrespectively of viral coreceptor phenotype. We next performed limiting dilutions of the same human milk sample and found that R5 and X4 HIV-1 variants were completely inhibited at a 1:128 but not at a 1:512 dilution (Figure 2B). Similar results were observed with the same assays using human milk from 2 other HIV-1–negative donors (data not shown).

**Human milk compound(s) bind to DC-SIGN, thereby preventing transfer of HIV-1 to CD4+ T lymphocytes.** To determine whether the inhibitory effect of human milk on Raji–DC-SIGN–mediated viral transfer was caused by interaction of human milk with HIV-1 or DC-SIGN, we conducted preincubation experiments of either Raji–DC-SIGN cells or HIV-1 with human milk. To test for binding of the inhibitory factor to Raji–DC-SIGN cells, we preincubated the cells with either a known inhibitory concentration of human milk (1:4) or PBS before washing and then adding virus and subsequently CD4+ T lymphocytes. Alternatively, to test binding of components in human milk to the virus, we incubated a high-titer virus stock with either PBS or human milk, after which the Raji–DC-SIGN cells were added, thereby diluting the milk to a noninhibitory concentration (1:667); CD4+ T lymphocytes were then added. Preincubation of virus with human milk demonstrated a slight reduction in viral transfer compared with the PBS control (Figure 3A), likely reflecting residual inhibitory effects of the human milk. In contrast, preincubation of the Raji–DC-SIGN cells with human milk provided a highly significant reduction in viral transfer compared with the PBS control ($P < 0.01$; Figure 3B). To test whether the observed inhibition was due to downmodulation of DC-SIGN expression, we investigated the surface expression of DC-SIGN in the presence of human milk. We demonstrate that with 2 DC-SIGN–specific mAbs, AZN-D2 and anti-stalk 4, cell surface expression was not altered, whereas

**Figure 3**
The human milk compound(s) interact with the DC-SIGN receptor, which does not lead to DC-SIGN downmodulation. (A) Human milk (1:4) or PBS was preincubated with a high-titer stock of LAI before adding to Raji–DC-SIGN cells at a dilution known not to inhibit viral replication. After incubation, the cells were washed, and CD4+ T lymphocytes were added, with CA-p24 values measured on day 15 by standard ELISA ($P > 0.01$). (B) Human milk (1:4) or PBS were incubated with Raji–DC-SIGN, after which the cells were washed to remove unbound human milk components before addition of LAI. After incubation, the cells were washed again, and CD4+ T lymphocytes were added, with the CA-p24 values measured on day 15 by standard ELISA. *$P < 0.01$. (C) Raji–DC-SIGN cells were incubated with TSM or human milk (1:2) before the binding of AZN-D1, AZN-D2, and anti-stalk 4 DC-SIGN–specific Abs were determined. The filled histograms represent the isotype control; the black lines represent the Ab binding without human milk preincubation; and the dotted lines represent the Ab binding after the cells were incubated with human milk.

**Figure 4**
DC-SIGN-Fc binding ELISA and the gp120 bead adhesion assay demonstrate the interaction of the human milk compound(s) with DC-SIGN. (A and B) Raji–DC-SIGN cells or iDCs, respectively, were incubated with human milk (1:20) before addition of fluorescent gp120–coated beads. DC-SIGN–positive cells and mock Raji cells were incubated with buffer as controls. To determine the specificity of the observed binding, the cells were incubated with AZN-D1, EGTA, and mannan before addition of the gp120 beads. *$P < 0.05$ compared with the PBS control. (C) Human milk (1:20) was coated before addition of DC-SIGN-Fc. The specificity of the observed binding was determined by the preincubation of DC-SIGN-Fc with AZN-D1 and EGTA. **$P < 0.01$ compared with the noninhibitory control. (D) Raji cells expressing the L-SIGN receptor were incubated with buffer, human milk (1:20), AZN-D1, AZN-D2, or mannan before addition of the gp120 fluorescent beads. *$P < 0.01$ compared with the binding without an inhibitor.
the binding of AZN-D1 was reduced when DC-SIGN cells were preincubated with human milk (Figure 3C). These results suggest that the inhibitory effect is mediated via the binding of factor(s) in human milk to the DC-SIGN molecule and prevention of its interaction with HIV-1 as opposed to the downmodulation of the DC-SIGN molecule at the cell surface.

To show direct binding of human milk compound(s) to DC-SIGN, we introduced 2 previously described assays (6, 56), the gp120 bead adhesion assay and the DC-SIGN-Fc binding ELISA. In the gp120 bead adhesion assay, the effect of human milk on the binding of gp120-coated fluorescent beads to cellular DC-SIGN was studied. The binding of the gp120 beads to both Raji-DC-SIGN and immature DCs (iDCs) was inhibited by human milk in comparison with the control (P < 0.01; Figure 4, A and B, respectively). To demonstrate DC-SIGN–specific binding, the cells were preincubated with a DC-SIGN–specific Ab (AZN-D1), the DC-SIGN–binding sugar mannan, and the Ca++ chelator EGTA. These agents were found to block binding of gp120 beads to the DC-SIGN–expressing cells to the same extent as human milk (Figure 4, A and B). To confirm the direct interaction of DC-SIGN with human milk, we performed a DC-SIGN-Fc binding ELISA where we demonstrated that DC-SIGN-Fc binding to human milk was specific, since preincubation of DC-SIGN-Fc with AZN-D1 or EGTA completely abrogated binding (P < 0.01; Figure 4C).

The liver and lymph node–specific homolog of DC-SIGN (liver and lymph node–specific ICAM3-grabbing non-integrin [L-SIGN]) is also capable of interacting with HIV-1 and enhancing viral infectivity (57). To investigate the effect of human milk on the interaction of L-SIGN and gp120, we incubated Raji cells expressing the L-SIGN molecule (Raji-L-SIGN) with human milk in the gp120 bead adhesion assay, and as a control, the cells were preincubated with AZN-D1, AZN-D2 (an L-SIGN–specific Ab), mannan, and EGTA. The results demonstrated that human milk did not inhibit the interaction of gp120 with L-SIGN (Figure 4D), indicating a specificity of the human milk compound for DC-SIGN.

**Human milk inhibits both iDC- and mature DC–dependent transfer of HIV-1.** To study the biological relevance of the inhibitory properties of human milk, we utilized a previously described single-cycle HIV-1 transmission assay (58) using both iDCs and mature DCs (mDCs). Either iDCs or mDCs [matured by poly d(I-C)] were incubated with several dilutions of human milk before addition of HIV-1 LAI (X4) and target cells. After 24 hours, luciferase activity was measured, representing transmission of HIV-1 to the LuSIV cells. Human milk was found to inhibit HIV-1–mediated transfer by both iDCs and mDCs (Figure 5A) in a dose-dependent manner, with the 2- and 5-fold dilutions showing significant inhibition for both cell types (P < 0.01). Washing after the preincubation of mDCs with human milk (1:2) before addition of HIV-1 also showed a significant reduction (P < 0.01) in HIV-1 transfer in comparison to the PBS control (data not shown), indicating that the observed inhibition shown in Figure 5A was not due to a direct virucidal effect of the human milk. We also demonstrated that a 1:2 and 1:5 dilution of human milk significantly reduces HIV-1 capture by iDCs and mDCs (P < 0.01; Figure 5B). We also tested for DC-SIGN downmodulation through cell-surface staining with the different Abs directed against DC-SIGN (AZN-D1, AZN-D2, and anti-stalk 4) in the presence or absence of human milk. Both AZN-D2 and anti-stalk 4 showed no significant difference in binding before and after human milk exposure, indicating that the DC-SIGN receptor is not downmodulated by the interaction with human milk (Figure 5C), while AZN-D1 does show a reduced binding after human milk exposure. We expect that similar results would
be obtained with an R5 virus and a CCR5-expressing cell, since we demonstrated that R5 and X4 viruses are equally inhibited with human milk (Figure 2).

Major human milk proteins do not bind DC-SIGN nor inhibit HIV-1 transfer to CD4+ T lymphocytes. Since inhibition by human milk is present at relatively high dilutions (Figure 2B), we hypothesized that one of the major proteins present in human milk may be responsible for the activity. We therefore tested human lactoferrin, bovine β-casein, human lysozyme, human α-lactalbumin, and human SLPI, which have been shown to possess modulatory effects on HIV-1 replication in vitro (44–49). All these compounds were tested in the gp120 bead adhesion assay and the DC-SIGN-Fc binding ELISA (Figure 6). None of the tested human milk compounds could inhibit gp120 binding to Raji-DC-SIGN or iDCs (Figure 6, A and B, respectively). Furthermore, DC-SIGN-Fc showed no binding to the selected milk compounds (Figure 6C). As a control, bovine lactoferrin was used, which has previously been shown to bind DC-SIGN and prevent viral transfer (58).

Preincubation of human milk with an anti-LeX Ab lifted the inhibition of HIV-1 transfer. Since DC-SIGN can bind sugars, we hypothesized that one of the abundant sugar motifs in human milk may provide the inhibitory activity (50–52). The fact that we demonstrated that gp120 binding to L-SIGN could not be inhibited with human milk (Figure 4D) and it is known that L-SIGN does not bind LeX motifs, we predicted that LeX could be contributing to the observed inhibition. To test our hypothesis, we preincubated human milk with an anti-LeX IgM Ab or an IgM isotype control before use in the culture transfer assay. The results demonstrated a dose-dependent lifting of the inhibitory effects of human milk on viral transfer after a preincubation with the LeX-specific Ab but not with the control Ab (Figure 7A). In contrast, the gp120 bead adhesion assay did not show reduced binding of DC-SIGN with LeX Ab (data not shown). The most likely explanation for this difference is that the low-affinity LeX-specific Ab was unable to block the high-avidity interaction of cellular multimeric DC-SIGN to the unknown human milk component. The DC-SIGN-Fc binding ELISA (Figure 7B) demonstrated a reduction in DC-SIGN-Fc binding after preincubation of the coated human milk with the LeX-specific Ab but again not with the control Ab. These results indicate that LeX is critical for the human milk compound that binds to the DC-SIGN molecule.

Not all LeX-containing complexes can inhibit HIV-1 interacting with the DC-SIGN receptor. We tested several compounds containing...
Multimeric and protein-associated Le\textsuperscript{x} inhibits DC-SIGN–mediated viral transfer. (A) Several Le\textsuperscript{x}-containing compounds showed a difference in their ability to block DC-SIGN–dependent transfer of HIV-1 to CD4\textsuperscript{+} T lymphocytes. The Le\textsuperscript{x}-trisaccharide, LNFP III, PAA-Le\textsuperscript{x}, Le\textsuperscript{x}-BSA, and control BSA were tested in the Raji-DC-SIGN culture transfer assay at concentrations of 10 µg/ml. The inhibition is depicted as a percentage of the Raji-DC-SIGN incubated with PBS. (B) Le\textsuperscript{x}-BSA and BSA as a control were coated before addition of DC-SIGN-Fc to determine the binding. DC-SIGN-Fc was preincubated with AZN-D1 and EGTA to determine the specificity of the observed binding. *P < 0.01 compared with both the AZN-D1 and EGTA control.

Discussion

C-type lectins, such as the DC-SIGN molecule, expressed on DCs have been postulated to play an important role in HIV-1 transmission and the establishment of initial HIV-1 infection (1, 2, 4, 6, 22–25). The interaction of DC-SIGN with the HIV-1 gp120 surface antigen can result in the efficient presentation of the virus to its target cells and can greatly heighten infection and virus replication (4, 6, 22–25). This mechanism is likely to play a role in MTCT of HIV-1 through breastfeeding, since virus transfer is required across a mucosal barrier. Virus present in human milk will likely encounter DCs situated at high concentrations within the tonsils, the esophagus (41, 42), and the intestines (43) that will thereby aid virus capture and subsequent transfer to CD4\textsuperscript{+} lymphocytes at the site of infection or in localized lymph nodes. In this study we demonstrate that human milk has a strong inhibitory effect on the DC-SIGN–mediated transfer of HIV-1 to CD4\textsuperscript{+} T lymphocytes, with R5 and X4 viruses being inhibited to the same extent. A component in human milk is interacting with the DC-SIGN molecule that prevents HIV-1 from binding to the receptor. We showed that lactoferrin, α-lactalbumin, lysozyme, β-casein, and SLPI were not responsible for the observed inhibition of HIV-1 interaction with DC-SIGN, even though these proteins can alter the direct infection of CD4\textsuperscript{+} T lymphocytes in vitro (44–49). Our results demonstrating that multimeric and protein-associated Le\textsuperscript{x} motifs can mimic the inhibitory activity of human milk and that the activity could be alleviated with a mAb recognizing the Le\textsuperscript{x} epitope suggest that a Le\textsuperscript{x} component in human milk is providing for the inhibition.

In the majority of our experiments, we utilized the DC-SIGN–expressing cell line (Raji-DC-SIGN) and the control Raji cell lacking DC-SIGN in order to demonstrate the DC-SIGN specificity of our results (8). We have also shown that human milk inhibits transfer of HIV-1 by both iDCs and mDCs, illustrating the biological relevance of the phenomenon, again with the inhibition being due to prevention of binding rather than DC-SIGN downmodulation. The expression levels of DC-SIGN have previously been shown to be higher on iDCs than mDCs (60); however, the human milk inhibited viral transfer by both cell types. This result indicates that the observed inhibition of mDC-dependent transfer may reflect the ability of human milk to block transfer of HIV-1 by other C-type lectins, such as the mannose receptor or the unidentified trypsin-resistant receptor (61). Whether the same Le\textsuperscript{x}-containing compound(s) or whether other sugar motifs in human milk can bind to other C-type lectin receptors remains to be determined. We did demonstrate, however, that the binding of HIV-1 to the DC-SIGN homolog L-SIGN is not inhibited by human milk. Our result corresponds with the previous observation that Le\textsuperscript{x} present in Schistosoma mansoni egg antigens (54) is able to interact with DC-SIGN but not with L-SIGN (62), reconfirming Le\textsuperscript{x} as a candidate for the observed inhibition of DC-SIGN–mediated transfer of HIV-1.

PAA-Le\textsuperscript{x} and Le\textsuperscript{x}-BSA successfully inhibited the DC-SIGN–mediated transfer of HIV-1. Conversely, both monomeric Le\textsuperscript{x} trisaccharide and LNFP III, a human milk sugar, do not inhibit viral transfer. Even though LNFP III has been shown previously to bind to DC-SIGN (59), this interaction does not lead to sufficient blocking of the HIV-1 interaction with DC-SIGN nor prevent viral transfer to CD4\textsuperscript{+} T lymphocytes. Multimeric Le\textsuperscript{x} was not able to inhibit gp120-coated beads binding to cellular DC-SIGN, possibly due to the high avidity of this interaction or the difference in interaction of the monomeric expression of gp120 on the fluorescent beads in comparison to trimeric expression of gp120 on the HIV-1 particle. The observed difference in the ability of Le\textsuperscript{x} Ab to block the inhibitory effect of human milk in the Raji-DC-SIGN transfer assay and the ELISA assay is possibly the result of differences in DC-SIGN configuration. On the cell surface, DC-SIGN is present as a tetramer, whereas in the DC-SIGN-Fc ELISA, the receptor is most likely a monomer or dimer, possibly leading to a weaker interaction. These differences in the configurations of the DC-SIGN molecules tested in the different assays suggest that caution should be applied when interpreting the results. It has been reported in previous studies that the Le\textsuperscript{x} and the gp120 binding sites are distinct but overlapping (54, 56, 63). An explanation for our observed inhibition by human milk could be that the larger...
compounds block the interaction of gp120 and DC-SIGN through steric hindrance by the larger tail. DC-SIGN forms a tetrameric structure on the cell surface (1) which could also cause occlusion of the gp120 binding site by interaction of several LeX residues with different monomeric DC-SIGN receptors. Most likely the interaction of several LeX motifs with the tetrameric DC-SIGN leads to a much stronger interaction of the compound and again prevents sufficient binding of gp120 and subsequent viral transfer.

It has been previously demonstrated that DC-SIGN can interact with an array of other pathogens, including hepatitis C (9, 10), Ebola (11), cytomegalovirus (12), and Dengue virus (13), as well as Mycobacterium (14–16), Leishmania (17, 18), Candida albicans (19), and Helicobacter pylori (20, 21). Interaction of LeX-containing human milk compounds with DC-SIGN may influence the immune responses mounted in the child to incoming pathogens by preventing their interaction with the DCs and thereby prevent the presentation of pathogen-specific antigens and the subsequent activation of CD4+ T lymphocytes. This may be a mechanism whereby levels of immune activation are buffered in a newborn to prevent overstimulation of the immune system or to skew specific immune responses in a certain direction. Indeed, it has previously been reported that mice immunized intranasally with LNFP III–HSA demonstrated a stronger induction of Th2-type immune responses versus Th1 (64). This result corresponds with the fact that LeX-positive Helicobacter pylori interactions with DC-SIGN can block Th1-induced cell responses, which results in a relative enhancement of the Th2 cell response (21), suggesting that LeX compounds in human milk can function as immunomodulatory factors. It will therefore be interesting to investigate whether breastfed versus bottle-fed infants have differences in their immune responses mounted against orally transmitted pathogens. It has also been reported that the baseline activation of lymphocytes is higher in bottle-fed than in breastfed infants (65). A number of explanations have been hypothesized, including differences in exposure to foreign proteins or a higher variety in intestinal microflora. Another possibility is that human milk compounds containing the LeX motif buffers the immune response by binding DC-SIGN and that these compounds are absent in formula or cow milk.

Future work will have to determine the biological significance of the interaction of the LeX-containing compounds with DC-SIGN with regard to the stimulation of the immune system and the relevance for MTCT of HIV-1 and other pathogens. Further identification and characterization of the specific LeX-containing compound(s) interacting with DC-SIGN may have major implications for the development of antimicrobial agents aiming at preventing HIV-1 transmission not only through breastfeeding but also through sexual activity.

Methods

Cells. The Raji control cell line and the cell lines expressing either DC-SIGN (Raji-DC-SIGN) or L-SIGN (Raji-L-SIGN) were cultured as previously described (4). PBMCs were isolated from buffy coats by standard Ficoll-Hypaque density centrifugation, activated with phytohemagglutinin (3 µg/ml), and cultured in RPMI medium containing 10% FCS, penicillin (100 units/ml), and streptomycin (100 units/ml). On day 3 the cells underwent CD4+ enrichment by incubation with CD8 immunomagnetic beads (Dynal Biotech) and were negatively selected according to the manufacturer’s instructions and cultured with IL-2 (100 U/ml). DCs for the single-cycle transmission assay were generated from fresh PBMCs with cells layered on a standard Percoll gradient (Amersham Pharmacia). The light fraction with predominantly monocytes was collected, washed, and seeded in 24-well or 6-well culture plates at a density of 5 × 10^6 cells or 2.5 × 10^6 per well, respectively. After 60 minutes at 37°C, the adherent cells were cultured to obtain iDCs in Iscove’s modified Dulbecco’s medium (IMDM) with gentamicin (86 µg/ml) and 10% fetal calf serum (HyClone) supplemented with GM-CSF (500 U/ml) and IL-4 (250 U/ml). Culture medium was refreshed on day 3, with cell maturation induced at day 6 by culturing with poly(I:C) (20 µg/ml; Sigma-Aldrich). After 2 days, mature CD14+ CD1b+ CD83+ DCs were obtained, washed, and utilized. The culture conditions for LusIV cells with an integrated long terminal repeat–luciferase reporter construct have been described previously (66).

Viruses. Replication-competent HIV-1 stocks were generated by the passage of viruses through CD4+ lymphocytes, with tissue culture infectious dose (TCID_{50}/ml) determined by limiting dilution on CD4+–enriched lymphocytes (67). Subtype B molecular cloned viruses JR-CSF (R5), LAI (X4), and SF-162 (R5) and subtype B primary isolates NSI-18 (R5) and SI-19 (X4) were used in the experiments.

Human milk fractions and commercial milk products. Internal review board approval was not required because samples were taken from discarded material from a single time point. Human milk samples were sequentially centrifuged at 400 g and 530 g for 10 minutes, with pipette removal of the lipid layers. Samples were sterilized by filtration through both 0.45-µm and 0.2-µm syringe filters (Schleicher & Schuell BioScience Inc.) and stored at −80°C. Human lactoferin (Sigma-Aldrich), bovine lactoferin (Sigma-Aldrich), human α-lactalbumin (Sigma-Aldrich), bovine β-casein (NIZO Food Research), human lysozyme (Sigma-Aldrich), LNFP III (Calbiochem), SLPI (Sigma-Aldrich), LeX trisaccharide (Calbiochem), LeX-BSA, 14-atom spacer (Calbiochem), PAA-LeX (Syntosyme), anti-human LeX mouse IgM (Calbiochem), and anti-human ARA-LAM (mouse) IgM were used. All compounds were utilized at physiologically relevant concentrations by dilution in PBS containing 10% FCS.

Direct HIV-1 infection assay. Enriched CD4+ lymphocytes were plated in 96-well plates at 1 × 10^6 cells/well in IL-2–containing culture medium. Cells were incubated for 2 hours with human milk diluted in PBS containing 10% FCS and spikied with 3.7 log TCID_{50}/ml of HIV-1. After 2 hours the cells were washed and fresh medium added. Alternatively, after a 2-hour incubation of human milk with HIV-1, the spikied milk was diluted with PBS containing 10% FCS before addition to CD4+ T lymphocytes. On day 7 of culture, viral capsid (CA-p24) levels were determined by ELISA.

DC-SIGN–mediated HIV-1 transfer assay. The Raji and Raji-DC-SIGN cell lines were plated at 2 × 10^4 cells/well in a 96-well format. Dilutions of human milk or human milk compounds were made in PBS containing 10% FCS and spikied with 3.7 log TCID_{50}/ml of the appropriate virus before addition to the Raji-DC-SIGN cells. As a control, PBS containing 10% FCS was spiked with the same TCID_{50}/ml of the corresponding virus before addition to Raji or Raji-DC-SIGN cells. After incubation the culture was washed with PBS before addition of CD4+–enriched T lymphocytes at a concentration of 1 × 10^6 cells/well, with CA-p24 determined on day 7.

DC-SIGN–specific Ab binding after exposure to human milk. Human milk was incubated with 50 × 10^4 Raji-DC-SIGN or iDCs for 15 minutes at 37°C, after which the cells were washed with TSM (20 mM Tris, 150 mM NaCl, 1 mM CaCl2, 2 mM MgCl2) and the cells were incubated at 4°C for 45 minutes with 5 µg/ml of the specific DC-SIGN Ab, AZN-D1 (6), AZN-D2 (12), or anti-stalk 4. Subsequently, the cells were washed and incubated with goat anti-mouse FITC for 45 minutes at 4°C. The cells were washed and resuspended in 100 µl TSM containing 0.5% BSA (Fraction V, Fatty Acid-Free; Calbiochem), and the adhesion was measured by flow cytometry (BD Biosciences).
DC-SIGN binding assay. For preincubation of HIV-1 with human milk, a 1:4 dilution of human milk or PBS containing 10% FCS was incubated with a high virus titer (5.6 log TCID₅₀/ml) of SF-162 for 1 hour at 37°C. Before diluting the mixture to 1:667 by addition of 0.27 × 10⁶ Raji-DC-SIGN cells in a 24-well format. The cells were incubated for 2 hours at 37°C before washing with PBS and addition of CD4⁺ T lymphocytes at a concentration of 1 × 10⁶ cells/ml followed by measuring CA-p24 production on day 15. For preincubation of Raji-DC-SIGN cells with human milk, a dilution of the human milk (1:4) or PBS containing 10% FCS was incubated with 0.27 × 10⁶ Raji-DC-SIGN cells in a 24-well format for 1 hour at 37°C before washing with PBS and addition of SF-162 (2.8 log TCID₅₀/ml). The cells were incubated for 2 hours before washing and adding 1 × 10⁶ cells/well of CD4⁺-enriched lymphocytes, with CA-p24 production measured on day 15.

gp120 bead adhesion assay. Beads were prepared as previously described (6). In short, streptavidin was covalently coupled to carboxyamide-modified TransFluoSpheres (488/645 nm excitation/emission, 1.0 µm; Invitrogen Corp.). The streptavidin beads were incubated with biotinylated F(ab')₂ fragment goat-anti-human IgG (6 µg/ml; Jackson ImmunoResearch Laboratories Inc.) and subsequently incubated overnight with gp120-Fc chimeras. Fifty thousand Raji-DC-SIGN cells, iDCs, or Raji-L-SIGN cells were preincubated with human milk or milk compounds, AZN-D1 (6), AZN-D2 (12), EGTA, or mannann for 30 minutes at room temperature. The ligand-coated beads (20 beads/cell) were added to the preincubated cells and incubated for 30 minutes at 37°C, after which the cells were washed with TSM containing 0.5% BSA. After washing, the cells were resuspended in 100 µl TSM-BSA buffer, and the adhesion was measured by flow cytometry (BD Biosciences).

DC-SIGN-Fc binding ELISA. This assay utilized the DC-SIGN-Fc chimera, which contained the extracellular portion of DC-SIGN (alpha acids 64–404) fused at the C terminus to a human IgG1 Fc fragment as previously described (56). Human milk or human milk compounds were diluted in 0.2 M NaHCO₃, coated on ELISA plates (Maxisorp plate; Nunc), and incubated overnight at 4°C or 2 hours at 37°C. This was followed by blocking with TSM containing 1% BSA for 30 minutes at 37°C before addition of soluble DC-SIGN-Fc (5 µg/ml) for 2 hours at room temperature; the binding was determined by incubation of a peroxidase-labeled anti-IgG1 Ab for 30 minutes at room temperature. DC-SIGN-Fc binding specificity was determined by preincubation of the DC-SIGN-Fc with either 50 µg/ml DC-SIGN–specific mouse Ab AZN-D1 (6) or 10 mM EGTA.

Single-cycle-replication transduction assay. The assay was performed as previously described (58). In short, mDCs and iDCs were incubated in a 96-well plate (35 × 10⁵ to 50 × 10⁴ DCs/well) with human milk for 30 minutes at 37°C before addition of virus (5 ng CA-p24/well), which was incubated for 2 hours at 37°C. The DCs were washed twice with PBS before addition of 50 × 10⁴ LuSIV cells. After 24 hours, LuSIV cells were harvested and resuspended in 50 µl lysis buffer (25 mM Tris-Cl 7.8, 2 mM DTT, 2 mM CDTA, 10% glycerol, 1% Triton X-100). The cells were then incubated for 45 minutes at room temperature while shaking, followed by 10 minutes centrifugation at 3,200 g. The supernatant was transferred to a white-solid 96-well plate (Costar; Corning), and 150 µl of buffer (100 µg/ml BSA, 6.6 mM ATP, 15 mM MgSO₄, 25 mM glycyglycine) was added. One hundred microliters of DC(-)Luciferin (Roche Diagnostics GmbH) was injected per well (0.28 mg/ml luciferin excluding ATP), LuSIV cells (50 × 10⁶) grown without DC or HIV-1 were used to obtain the background luciferase value.

Capture assay. To measure the capture of HIV-1 by iDCs, the cells were incubated in a 96-well plate (50 × 10⁴ DCs/well) with human milk for 30 minutes at 37°C before addition of the virus (5 ng CA-p24/well), which was incubated for 2 hours at 37°C. The iDCs were washed twice with PBS before the CA-p24 concentration was determined by standard ELISA.

Statistics. All statistical comparisons were performed using ANOVA. P < 0.01 and P < 0.05 were considered statistically significant.

Acknowledgments
This work was funded through grants from the Elizabeth Glaser Pediatric AIDS Foundation (27-PG-51269), the Royal Dutch Academy of Arts and Sciences (to W.A. Paxton), and the Dutch AIDSfonds (7008). We are indebted to the mothers for providing milk samples and thank Michel de Baar for critical review of the manuscript, Stef Heynen for his expert technical assistance, and Wim van Est for the artwork.

Received for publication March 22, 2005, and accepted in revised form August 23, 2005.

Teunis B.H. Geijtenbeek and Georgios Pollakis contributed equally to this work.

Address correspondence to: William A. Paxton, Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands. Phone: 31-20-5664739; Fax: 31-20-6916531; E-mail: w.a.paxton@amc.uva.nl.


